Zenocutuzumab Biosimilar

Zenocutuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB2/ERBB3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).

Target	ERBB2/ERBB3
Research Area	Humanized Monoclonal Antibodies, Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95% (SDS-PAGE)
Purification	Purified from cell culture supernatant by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
UniProt Primary AC	P04626 (UniProt, ExPASy) P21860 (UniProt, ExPASy)
Buffer	0.01 M PBS, pH 7.4.
CAS Number	1969309-56-5
Concentration	1.96 mg/ml
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on ERBB2/ERBB3

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue